Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Revenue (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Revenue for 15 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 7.87% year-over-year to $2.1 million, compared with a TTM value of $9.0 million through Oct 2025, down 5.34%, and an annual FY2025 reading of $9.0 million, down 5.34% over the prior year.
  • Revenue was $2.1 million for Q4 2025 at Pharma-Bio Serv, up from $2.0 million in the prior quarter.
  • Across five years, Revenue topped out at $5.6 million in Q4 2021 and bottomed at $2.0 million in Q3 2025.
  • Average Revenue over 5 years is $3.8 million, with a median of $4.4 million recorded in 2021.
  • The sharpest move saw Revenue increased 11.83% in 2022, then tumbled 47.9% in 2024.
  • Year by year, Revenue stood at $5.6 million in 2021, then fell by 17.13% to $4.6 million in 2022, then decreased by 22.42% to $3.6 million in 2023, then crashed by 35.15% to $2.3 million in 2024, then dropped by 7.87% to $2.1 million in 2025.
  • Business Quant data shows Revenue for PBSV at $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.4 million in Q2 2025.